Announcement of Availability for Mirdametinib

July 27, 2022

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using mirdametinib, a highly selective, brain penetrant, orally bioavailable small molecule MEK inhibitor, which is being developed by CTEP as an anticancer agent in collaboration with SpringWorks Therapeutics, Inc. CTEP will also consider requests to supply mirdametinib for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study

Questions may be addressed to Dr. Rabih Said (rabih.said@nih.gov), Medical Officer, Investigational Drug Branch, CTEP.

For more information please see related documents below.